Guggenheim Reaffirms “Buy” Rating for Dyne Therapeutics (NASDAQ:DYN)

Dyne Therapeutics (NASDAQ:DYN)‘s stock had its “buy” rating reiterated by Guggenheim in a report released on Friday,Benzinga reports.

A number of other brokerages have also recently weighed in on DYN. HC Wainwright reissued a “buy” rating and set a $55.00 price target on shares of Dyne Therapeutics in a research report on Friday, January 10th. Robert W. Baird initiated coverage on Dyne Therapeutics in a research report on Friday, December 13th. They issued an “outperform” rating and a $46.00 price objective for the company. Royal Bank of Canada reissued an “outperform” rating and set a $45.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. Baird R W upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Finally, Chardan Capital restated a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a report on Friday, January 10th. One analyst has rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $49.91.

Dyne Therapeutics Price Performance

Shares of DYN stock traded down $0.17 during trading hours on Friday, reaching $13.52. The company had a trading volume of 564,242 shares, compared to its average volume of 2,421,110. Dyne Therapeutics has a 1-year low of $13.49 and a 1-year high of $47.45. The company has a 50 day moving average of $24.32 and a 200 day moving average of $32.77. The firm has a market cap of $1.38 billion, a price-to-earnings ratio of -3.79 and a beta of 1.16.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). As a group, sell-side analysts forecast that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, Director Carlo Incerti sold 16,500 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $28.73, for a total value of $474,045.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Jason P. Rhodes sold 782 shares of the company’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $33.10, for a total transaction of $25,884.20. Following the completion of the transaction, the director now owns 15,962 shares in the company, valued at $528,342.20. This trade represents a 4.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 21,071 shares of company stock worth $606,476 over the last quarter. 20.77% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in DYN. FMR LLC boosted its position in shares of Dyne Therapeutics by 69.7% during the 3rd quarter. FMR LLC now owns 9,026,697 shares of the company’s stock valued at $324,239,000 after purchasing an additional 3,707,734 shares in the last quarter. RTW Investments LP raised its holdings in Dyne Therapeutics by 6.8% during the third quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock worth $244,926,000 after buying an additional 431,503 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of Dyne Therapeutics by 47.3% in the 3rd quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company’s stock worth $244,755,000 after acquiring an additional 2,189,339 shares during the last quarter. RA Capital Management L.P. lifted its holdings in shares of Dyne Therapeutics by 5.5% in the third quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after purchasing an additional 331,940 shares in the last quarter. Finally, State Street Corp lifted its stake in Dyne Therapeutics by 13.8% during the 3rd quarter. State Street Corp now owns 3,641,859 shares of the company’s stock valued at $130,816,000 after acquiring an additional 440,890 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.